<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169507</url>
  </required_header>
  <id_info>
    <org_study_id>104083</org_study_id>
    <nct_id>NCT00169507</nct_id>
  </id_info>
  <brief_title>Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)</brief_title>
  <official_title>Phase III Multicentric Open Study to Evaluate Immunological Memory Induced by 3-dose Primary Vaccination Followed by Booster Dose of GSK Biologicals' 11-valent Conjugate Pneumococcal Vaccine Compared to Unprimed Subjects by Giving 1 Dose of Aventis Pasteur's Pneumo 23</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Evaluate the immunological memory induced by 4 doses of GSK Biologicals' 11valent
      pneumococcal vaccine; study antibody persistence 30 months after the 4 dose vaccination with
      GSK Biologicals' 11-valent pneumococcal vaccine in Undeca-Pn-010 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primed group: 50 subjects who previously received 4 doses of GSK Biologicals' 11Pn-PD vaccine
      will receive 1 dose of Pneumo 23 Unprimed group (Control): 50 subjects who received GSK
      Biologicals' Havrix™ vaccine will receive 1 dose of Pneumo 23
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody concentrations (ELISA) to pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F 10-15 days after the single dose of Aventis Pasteur's 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Before Pneumo 23 administration: Antibody concentrations (ELISA) to pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F &amp; seropositivity (S+) status* (&gt;= 0.05 µg/mL) * also measured 10-15 days after dose of Pneumo 23</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Before and 10-15 days after dose of Pneumo 23: Antibody titers (opsono) to selected pneumococcal serotypes and S+ status (&gt;= 8)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs during study period</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Prophylaxis Pneumococcal Vaccine</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal (vaccine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Male or female who participated in Undeca-Pn-010 study, were part of
        the blood subset and received 4 doses of GSK Biologicals' 11Pn-PD vaccine, or Havrix
        vaccine. Exclusion criteria: Use of any investigational or non-registered drug or vaccine
        other than the study vaccine within 30 days preceeding the first dose of study vaccine, or
        planned use during the study period. Administration of any additional pneumococcal vaccine
        since study end of Undeca-Pn-010 (347414/010)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Months</minimum_age>
    <maximum_age>57 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dubnica Nad Vahom</city>
        <zip>018 41</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nova Dubnica</city>
        <zip>018 51</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>017 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puchov</city>
        <zip>020 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

